Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

Abstract Background Patient-reported outcomes (PROs) are important when evaluating treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to assess clinically meaningful improvements in PROs in patients with RA who have had inadequ...

Full description

Bibliographic Details
Main Authors: Vibeke Strand, Michael Schiff, Namita Tundia, Alan Friedman, Sebastian Meerwein, Aileen Pangan, Arijit Ganguli, Mahesh Fuldeore, Yan Song, Janet Pope
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Patient-reported outcome measures
JAK inhibitor
Quality of life
Treatment outcomes
Upadacitinib
Online Access:https://doi.org/10.1186/s13075-019-2059-8

Internet

https://doi.org/10.1186/s13075-019-2059-8

Similar Items